An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion

American Journal of Rhinology

Volumn 11, Issue 2, 1997, Pages 109-115

  Morris, Sara ^a   Eccles, Ronald ^a   Martez, S Jawad ^a   Riker, Donald K ^b   Witek, Theodore J ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECONGESTIVE AGENT; OXYMETAZOLINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INTERMITTENT THERAPY; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; NOSE AIRWAY RESISTANCE; NOSE CONGESTION; RANDOMIZED CONTROLLED TRIAL; REBOUND; RHINOMANOMETRY; VOLUNTEER;

EID: 0030999348     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: 10.2500/105065897782537197     Document Type: Article

References (20)

1. Gollum J. The problem of nasal medication with particular reference to privine HCl 0.1%. Can Med Assoc J 51:123-126, 1944.
2. Stride RO. Nasal decongestant therapy. Br J Clin Pract 21:541-548, 1967.
3. Toohill RJ, Lehman RH, Grossman TW, Belson TP. Rhinitis medicamentosa. Laryngoscope 91:1614-1621, 1981.
4. Federal Register Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Over-the-Counter Nasal Decongestant Drug Products. January 15 50:2232, 1985.
5. ABPI Data Sheet Compendium Datapharm Publications Limited, London (1994-1995).
6. Schumacher MJ. Rhinomanometry. J Allergy Clin Immunol 83:711-719, 1989.
7. Biesalski P, Marquardt K. Zur behandlung der rhinitis im fruhen kindesalter. Thermoelektrische Untersuchungen an abschwellenden nasenmitteln. (Treatment of rhinitis of early childhood. Thermoelectric studies on decongestant nasal drugs). Schweizerische Medizinische Wohenschrift 89:510-512, 1959.
8. Messek H. Die Wirkung verscheidener vasokonstriktoria auf einige qualitäten der nasenschleimhaut. (The effect of different vasoconstrictors on various qualities of the nasal mucosa). Monatssehriff fur Ohrenheilkunde und Laryngo-Rhinologie 96:294-306, 1962.
9. Rudiger W. Untersuchungen uber die luftdurchgängigkeit der nase unter Anwendung eines neuen gefäßverengenden mittels. (Investigation of the passibility of air through the nose under the effect of a new vasoconstricting agent). HNO Wegeiser 7:77-80, 1958.
10. Graf P, Juto JE. Decongestion effect and rebound swelling of the nasal mucosa during 4-week use of oxymetazoline. ORL 56:157-160, 1994.
11. Petruson B. Treatment, with xylometazoline (Otrivin®) nose-drops over a six-week period. Rhinology 19:167-172, 1981.
12. Connell JT, Linzmayer I. Studies of rebound phenomena and oxymetazoline. J Allergy Clin Immunol 81:179, 1988.
13. Van de Donk HJM, Muller-Plantema IP, Zuidema J, Merkus FWHM. The effects of preservatives on the ciliary beat frequency of chicken embryo tracheas. Rhinology 18:119-133, 1980.
14. Batts AH, Marriott C, Martin GP, Bond SW. The effects of some preservatives used in nasal preparations on mucociliary clearance. J Pharm Pharmacol 41:156-159, 1989.
15. Deitmer T, Scheffler R. The effect of different preparations of nasal decongestants on ciliary beat frequency in vitro. Rhinology 31:151-153, 1993.
16. Cole P, Foryth R, Haight JSM. Effects of cold air and exercise on nasal patency. Ann Otol Rhinol Laryngol 92:196-198, 1983.
17. Olsson P, Bende M. Influence of environmental temperature on human nasal mucosa. Ann Otol Rhinol Laryngol 94:153-155, 1985.
18. Hardcastle PF, White A, Prescott RJ. Clinical or rhinometric assessment of the nasal airway - which is better? Clin Otolaryngol 13:381-385, 1988.
19. Black MJ, Remsen KA. Rhinitis medicamentosa. Can Med Assoc J 122:881-884, 1980.
20. Silves W, Lutsky B, Mooney J, et al. Defining rhinitis medicamentosa, rebound, and tolerance using anterior rhinoscopy and rhinomanometry. J Allergy Clin Immunol 87:150, 1991.